3:44 PM
 | 
Jul 24, 2017
 |  BC Extra  |  Clinical News

Reata gains as bardoxolone study moves to Phase III

Reata Pharmaceuticals Inc. (NASDAQ:RETA) gained $4.37 (14%) to $35.47 on Monday after saying it will move ahead to the Phase III portion of the Phase II/III CARDINAL study of bardoxolone methyl (RTA 402) to treat chronic kidney disease (CKD) caused by Alport syndrome.

Data...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >